REVOLUTIONIZING DFU TREATMENT: ESCHAREX - A GAME-CHANGING SOLUTION
Location: Israel
Source: EU Funding & Tenders Portal
INTRODUCTION: MediWound develops wound care solutions, for chronic wounds and severe burns. The Company’s leading drug candidate under development and the subject of this EIC Accelerator project is EscharEx®, a groundbreaking bioactive therapy specifically targeting the debridement of Diabetic Foot Ulcers (DFUs) and other challenging chronic wounds. EscharEx is poised to revolutionize the standard
- Status
- Under Construction
- Location
- Israel
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about REVOLUTIONIZING DFU TREATMENT: ESCHAREX - A GAME-CHANGING SOLUTION
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | ongoing |
Taiyo status | Under Construction |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | INTRODUCTION: MediWound develops wound care solutions, for chronic wounds and severe burns. The Company’s leading drug candidate under development and the subject of this EIC Accelerator project is EscharEx®, a groundbreaking bioactive therapy specifically targeting the debridement of Diabetic Foot Ulcers (DFUs) and other challenging chronic wounds. EscharEx is poised to revolutionize the standard of care (SOC) that for many patients is ineffective. EscharEx - A GAME-CHANGER IN CHRONIC WOUND CARE: EscharEx is a complex mixture of proteolytic enzymes, primarily bromelain, designed to selectively remove necrotic tissue and biofilm from chronic wounds. This process is highly efficient and does not harm viable tissue, providing an optimal wound bed for healing. Unlike traditional knife-based debridement, which can be traumatic and painful, EscharEx offers a non-surgical alternative that is swift, safe and effective. This aspect is especially critical for diabetic patients, often elderly and suffering from co-morbidities, who may find surgical options less suitable. The currently available non-surgical options are notoriously slow and ineffective, causing delays to the wound healing process, and resulting in significant incremental costs and poorer overall outcomes. CLINICAL PROGRESS AND VALIDATION: MediWound's confidence in EscharEx stems from the outcomes of three Phase 2 clinical studies. These studies demonstrated the therapy's rapid, safe, and effective debridement of DFUs and Venous Leg Ulcers (VLUs). Additionally, EscharEx shares the same active pharmaceutical ingredient as NexoBrid, MediWound's EMA and FDA-approved drug product for debridement of severe burn wounds. The consistency of active ingredients and similarity of indications between these two drugs provides additional support for the increased probability of success for EscharEx development and highlight the scientific rigor behind EscharEx's development. |
Location
Country | Israel |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Article published date | 2026-03-01 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
